Novavax | NVAX - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Adma Biologics USD 26.74M 5K 2026-06
Agenus USD 6.21M 4.34M 2026-03
AstraZeneca USD 4.07B 1.73B 2026-09
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Cassava Sciences USD 3.37M 521K 2026-06
Geron USD 35.7M 3.16M 2026-09
GlaxoSmithKline GBP 2.16B 39M 2026-09
MannKind USD 61.41M 3.11M 2026-09
Merck USD 2.86B 25M 2026-09
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Moderna USD 282M 66M 2026-09
Novartis USD 3.08B 58M 2026-09
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 3.28B 132M 2026-09
Sanofi EUR 2.31B 325M 2026-09
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
TG Therapeutics USD 62.32M 10.82M 2026-06